Drug Profile


Alternative Names: hpNSC; Human parthenogenetic neural stem cells - International Stem Cell Corporation; ISC-hpNSC

Latest Information Update: 20 Oct 2016

Price : $50

At a glance

  • Originator Duke University; International Stem Cell Corporation
  • Developer International Stem Cell Corporation; Tulane University
  • Class Antiparkinsonians; Cell therapies; Stem cell therapies
  • Mechanism of Action Dopaminergic cell replacements; Nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Parkinson's disease
  • Preclinical Brain injuries; Stroke

Most Recent Events

  • 18 Oct 2016 Preclinical trials in Brain injuries in USA (unspecified route)
  • 18 Oct 2016 International Stem Cell Corporation announces intention to submit regulatory application to initiate clinical studies for Brain injuries
  • 31 Mar 2016 International Stem Cell Corporation plans a clinical trial in Stroke
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top